齐齐哈尔医学院学报
齊齊哈爾醫學院學報
제제합이의학원학보
JOURNAL OF QIQIHAR MEDICAL COLLEGE
2015年
10期
1416-1418
,共3页
罗海清%李祥勇%蔡宏华%刘付梅%崔仲宜%官成浓
囉海清%李祥勇%蔡宏華%劉付梅%崔仲宜%官成濃
라해청%리상용%채굉화%류부매%최중의%관성농
奈达铂%BI-1基因%鼻咽癌
奈達鉑%BI-1基因%鼻嚥癌
내체박%BI-1기인%비인암
Nedaplatin%BI-1 gene%Nasopharyngeal carcinoma
目的:研究奈达铂联合靶向沉默BI-1基因对鼻咽癌细胞CNE-2增殖和凋亡的影响。方法采用MTT法检测奈达铂联合靶向沉默BI-1基因对鼻咽癌细胞CNE-2增殖的抑制作用。采用流式细胞技术检测奈达铂联合靶向沉默BI-1基因对鼻咽癌细胞CNE-2凋亡的影响。结果奈达铂联合靶向沉默BI-1基因呈时间和剂量依赖性抑制鼻咽癌细胞株CNE-2的增殖,奈达铂联合靶向沉默BI-1基因呈剂量依赖性诱导鼻咽癌细胞CNE-2的凋亡。结论研究结果证实奈达铂联合靶向沉默BI-1基因能有效抑制鼻咽癌细胞CNE-2的增殖,并能诱导鼻咽癌细胞CNE-2的凋亡。这种化疗联合靶向治疗的模式以期为鼻咽癌的治疗提供一种新的高效低毒的治疗模式。
目的:研究奈達鉑聯閤靶嚮沉默BI-1基因對鼻嚥癌細胞CNE-2增殖和凋亡的影響。方法採用MTT法檢測奈達鉑聯閤靶嚮沉默BI-1基因對鼻嚥癌細胞CNE-2增殖的抑製作用。採用流式細胞技術檢測奈達鉑聯閤靶嚮沉默BI-1基因對鼻嚥癌細胞CNE-2凋亡的影響。結果奈達鉑聯閤靶嚮沉默BI-1基因呈時間和劑量依賴性抑製鼻嚥癌細胞株CNE-2的增殖,奈達鉑聯閤靶嚮沉默BI-1基因呈劑量依賴性誘導鼻嚥癌細胞CNE-2的凋亡。結論研究結果證實奈達鉑聯閤靶嚮沉默BI-1基因能有效抑製鼻嚥癌細胞CNE-2的增殖,併能誘導鼻嚥癌細胞CNE-2的凋亡。這種化療聯閤靶嚮治療的模式以期為鼻嚥癌的治療提供一種新的高效低毒的治療模式。
목적:연구내체박연합파향침묵BI-1기인대비인암세포CNE-2증식화조망적영향。방법채용MTT법검측내체박연합파향침묵BI-1기인대비인암세포CNE-2증식적억제작용。채용류식세포기술검측내체박연합파향침묵BI-1기인대비인암세포CNE-2조망적영향。결과내체박연합파향침묵BI-1기인정시간화제량의뢰성억제비인암세포주CNE-2적증식,내체박연합파향침묵BI-1기인정제량의뢰성유도비인암세포CNE-2적조망。결론연구결과증실내체박연합파향침묵BI-1기인능유효억제비인암세포CNE-2적증식,병능유도비인암세포CNE-2적조망。저충화료연합파향치료적모식이기위비인암적치료제공일충신적고효저독적치료모식。
Objective The effect of Nedaplatin and silence BI-1 gene on proliferation and apoptosis of CNE-2 Nasopharyngeal carcinoma cells was studied.Methods Nedaplatin combined with silence BI-1 gene inhibited proliferation of CNE-2 Nasopharyngeal carcinoma cells, as detected using tetrazolium colorimetric assay. Cellular apoptosis of CNE-2 Nasopharyngeal carcinoma cells induced by Nedaplatin combined with silence BI-1 gene was measured by flow cytometry.Results Nedaplatin combined with silence BI-1 gene showed inhibition of proliferation of CNE-2 Nasopharyngeal carcinoma cells in a dose-and time-dependent manner. Moreover Nedaplatin combined with silence BI-1 gene could promote apoptosis of CNE-2 Nasopharyngeal carcinoma cells in a dose-dependent manner.Conclusions The chemotherapy combined with targeted therapy will provide a new treatment mode with high efficiency and low toxicity for treatment of nasopharyngeal carcinoma.